Bender Robert & Associates Has $900,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Bender Robert & Associates raised its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,507 shares of the company’s stock after buying an additional 400 shares during the quarter. Bender Robert & Associates’ holdings in Johnson & Johnson were worth $900,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. DORCHESTER WEALTH MANAGEMENT Co increased its position in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P increased its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. increased its position in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. increased its position in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd increased its position in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ opened at $173.43 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The business’s 50-day moving average price is $176.32 and its two-hundred day moving average price is $171.55. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $453.43 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 3.45 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the prior year, the firm posted $2.60 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Morgan Stanley lowered their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Atlantic Securities lowered their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Barclays initiated coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target on the stock. Bank of America lowered their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Finally, Sanford C. Bernstein lowered their price target on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $182.42.

Insider Transactions at Johnson & Johnson

In other news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock valued at $52,311,677 over the last 90 days. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.